Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
Malagola M, Martinelli G, Rondoni M, Paolini S, Gaitani S, Arpinati M, Piccaluga PP, Amabile M, Basi C, Ottaviani E, Candoni A, Gottardi E, Cilloni D, Bocchia M, Saglio G, Lauria F, Fanin R, Visani G, Marrè MC, Maderna M, Rancati F, Vinaccia V, Russo D, Baccarani M. Malagola M, et al. Among authors: rancati f. Blood. 2005 Jan 15;105(2):904; author reply 905. doi: 10.1182/blood-2004-08-3088. Blood. 2005. PMID: 15632213 Free article. No abstract available.
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
Piccaluga PP, Malagola M, Rondoni M, Arpinati M, Paolini S, Candoni A, Fanin R, Messa E, Pirrotta MT, Lauria F, Visani G, Alberti D, Rancati F, Vinaccia V, Russo D, Saglio G, Baccarani M, Martinelli G. Piccaluga PP, et al. Among authors: rancati f. Haematologica. 2007 Dec;92(12):1721-2. doi: 10.3324/haematol.11345. Haematologica. 2007. PMID: 18056005 Free article. Clinical Trial.
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. Baccarani M, et al. Among authors: rancati f. Haematologica. 2007 Sep;92(9):1173-9. doi: 10.3324/haematol.11420. Epub 2007 Aug 1. Haematologica. 2007. PMID: 17666373 Free article.
Glivec and CML: a lucky date.
Saglio G, Cilloni D, Rancati F, Boano L. Saglio G, et al. Among authors: rancati f. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):246-51. J Biol Regul Homeost Agents. 2004. PMID: 15739279 Review.
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G. Petzer AL, et al. Among authors: rancati f. Haematologica. 2010 Jun;95(6):908-13. doi: 10.3324/haematol.2009.013979. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145273 Free PMC article. Clinical Trial.
Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
Carzaniga L, Linney ID, Rizzi A, Schmidt W, Knight CK, Mileo V, Amadei F, Pastore F, Miglietta D, Cesari N, Riccardi B, Mazzucato R, Ghidini E, Blackaby WP, Patacchini R, Battipaglia L, Villetti G, Puccini P, Catinella S, Civelli M, Rancati F. Carzaniga L, et al. Among authors: rancati f. J Med Chem. 2024 Jun 27;67(12):9816-9841. doi: 10.1021/acs.jmedchem.4c00298. Epub 2024 Jun 10. J Med Chem. 2024. PMID: 38857426
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
Carzaniga L, Linney ID, Rizzi A, Delcanale M, Schmidt W, Knight CK, Pastore F, Miglietta D, Carnini C, Cesari N, Riccardi B, Mileo V, Venturi L, Moretti E, Blackaby WP, Patacchini R, Accetta A, Biagetti M, Bassani F, Tondelli M, Murgo A, Battipaglia L, Villetti G, Puccini P, Catinella S, Civelli M, Rancati F. Carzaniga L, et al. Among authors: rancati f. J Med Chem. 2022 Aug 11;65(15):10233-10250. doi: 10.1021/acs.jmedchem.2c00609. Epub 2022 Jul 28. J Med Chem. 2022. PMID: 35901125
16 results